Eli Lilly Cash on Hand 2010-2024 | LLY
Eli Lilly cash on hand from 2010 to 2024. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
- Eli Lilly cash on hand for the quarter ending September 30, 2024 was $3.518B, a 41.08% increase year-over-year.
- Eli Lilly cash on hand for 2023 was $2.928B, a 32.37% increase from 2022.
- Eli Lilly cash on hand for 2022 was $2.212B, a 43.41% decline from 2021.
- Eli Lilly cash on hand for 2021 was $3.909B, a 6.17% increase from 2020.
Eli Lilly Annual Cash on Hand
(Millions of US $) |
| 2023 |
$2,928 |
| 2022 |
$2,212 |
| 2021 |
$3,909 |
| 2020 |
$3,681 |
| 2019 |
$2,439 |
| 2018 |
$7,409 |
| 2017 |
$8,034 |
| 2016 |
$6,039 |
| 2015 |
$4,452 |
| 2014 |
$4,827 |
| 2013 |
$5,397 |
| 2012 |
$5,684 |
| 2011 |
$6,897 |
| 2010 |
$6,727 |
| 2009 |
$4,498 |
Eli Lilly Quarterly Cash on Hand
(Millions of US $) |
| 2024-09-30 |
$3,518 |
| 2024-06-30 |
$3,364 |
| 2024-03-31 |
$2,586 |
| 2023-12-31 |
$2,928 |
| 2023-09-30 |
$2,494 |
| 2023-06-30 |
$2,829 |
| 2023-03-31 |
$3,669 |
| 2022-12-31 |
$2,212 |
| 2022-09-30 |
$2,742 |
| 2022-06-30 |
$2,737 |
| 2022-03-31 |
$2,568 |
| 2021-12-31 |
$3,909 |
| 2021-09-30 |
$3,825 |
| 2021-06-30 |
$3,271 |
| 2021-03-31 |
$3,051 |
| 2020-12-31 |
$3,681 |
| 2020-09-30 |
$3,630 |
| 2020-06-30 |
$2,388 |
| 2020-03-31 |
$1,777 |
| 2019-12-31 |
$2,439 |
| 2019-09-30 |
$1,653 |
| 2019-06-30 |
$2,368 |
| 2019-03-31 |
$2,137 |
| 2018-12-31 |
$7,409 |
| 2018-09-30 |
$9,036 |
| 2018-06-30 |
$6,910 |
| 2018-03-31 |
$4,790 |
| 2017-12-31 |
$8,034 |
| 2017-09-30 |
$6,943 |
| 2017-06-30 |
$5,434 |
| 2017-03-31 |
$3,506 |
| 2016-12-31 |
$6,039 |
| 2016-09-30 |
$4,227 |
| 2016-06-30 |
$3,935 |
| 2016-03-31 |
$2,995 |
| 2015-12-31 |
$4,452 |
| 2015-09-30 |
$4,319 |
| 2015-06-30 |
$4,231 |
| 2015-03-31 |
$4,140 |
| 2014-12-31 |
$4,827 |
| 2014-09-30 |
$4,810 |
| 2014-06-30 |
$5,127 |
| 2014-03-31 |
$5,212 |
| 2013-12-31 |
$5,397 |
| 2013-09-30 |
$5,379 |
| 2013-06-30 |
$4,711 |
| 2013-03-31 |
$4,732 |
| 2012-12-31 |
$5,684 |
| 2012-09-30 |
$6,900 |
| 2012-06-30 |
$5,262 |
| 2012-03-31 |
$4,925 |
| 2011-12-31 |
$6,897 |
| 2011-09-30 |
$6,784 |
| 2011-06-30 |
$6,330 |
| 2011-03-31 |
$6,713 |
| 2010-12-31 |
$6,727 |
| 2010-09-30 |
$6,140 |
| 2010-06-30 |
$5,197 |
| 2010-03-31 |
$4,758 |
| 2009-12-31 |
$4,498 |
| 2009-09-30 |
$3,929 |
| 2009-06-30 |
$3,490 |
| 2009-03-31 |
$3,508 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$777.423B |
$34.124B |
|
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
|
